Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

Visuri, Isabella; Eriksson, Carl; Karlqvist, Sara; Lykiardopoulos, Byron; Karlén, Per; Grip, Olof; Söderman, Charlotte; Almér, Sven; Hertervig, Erik; Marsal, Jan; Malmgren, Carolina; Delin, Jenny; Strid, Hans; Sjöberg, Mats; Bergemalm, Daniel; Hjortswang, Henrik; Halfvarson, Jonas

doi:10.1177/17562848231174953

Public

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

Published in Therapeutic Advances in Gastroenterology • Jan 1, 2023

Authors:

Isabella Visuri

Carl Eriksson

Sara Karlqvist

Abstract

Background: Real-world data on long-term outcomes of vedolizumab (VDZ) are scarce. Objective: To assess long-term outcomes (up to 3 years) of VDZ in treating inflammatory bowel disease (IBD). Design: A nationwide, prospective multicentre extension of a Swedish observational study on VDZ assessing Ef...

Subject

Medicine

Vedolizumab

Inflammatory bowel disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!